Skip to main content

Table 4 Multiple linear regression analysis for associations of ICIs with absolute volume progression, absolute score progression, relative volume progression, and relative score progression of CAC at 12 months after PSM

From: Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium

 

Model 1

Model 2

Model 3

 

Beta (SE)

p-value

Beta (SE)

p-value

Beta (SE)

p-value

Absolute volume progression

0.197 (0.081)

0.015

0.191 (0.082)

0.020

0.165 (0.061)

0.007

Absolute score progression

0.240 (0.081)

0.003

0.238 (0.083)

0.004

0.188 (0.061)

0.002

Relative volume progression

0.223 (0.081)

0.006

0.213 (0.083)

0.010

0.244 (0.079)

0.002

Relative score progression

0.224 (0.082)

0.006

0.232 (0.083)

0.005

0.233 (0.081)

0.004

  1. Abbreviations: ICI immune checkpoint inhibitor, CAC coronary artery calcium, SE standard error, PSM propensity score matching
  2. Model 1 is adjusted for sex, age, and history of cardiovascular disease
  3. Model 2 is adjusted for body mass index, hypertension, diabetes, smoking index, hyperlipidemia, chest radiation therapy, statins, aspirin, hemoglobin, neutrophil-to-lymphocyte ratio, and platelet count to lymphocyte ratio in addition to the variables in the model 1
  4. Model 3 is adjusted for baseline coronary artery calcium volume and score, in addition to the variables in the model 2
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us